COO Cooper Companies (The)

Q1 2026 10-Q
Filed: Mar 6, 2026Period ending Jan 31, 2026
Health Care
Ophthalmic GoodsSEC EDGAR

Cooper Companies (The) (COO) 10-Q quarterly report for Q1 2026, filed with SEC EDGAR on Mar 6, 2026 for the fiscal period ending Jan 31, 2026. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q1 2026 10-Q

Management Discussion & Analysis

  • Total revenue $1,024.1M (CooperVision $695.1M + CooperSurgical $329.0M) vs $964.7M Q1 FY2025, up ~6% YoY
  • Consolidated gross margin flat at 68%; operating margin 20.8% vs 18.9% YoY; CooperVision operating margin 30.2% vs 28.5%; CooperSurgical 8.1% vs 6.3%
+3 more insights

Risk Factors

  • No material changes from 10-K (fiscal year ended Oct 31, 2025); all prior risk factors carried forward unchanged
  • Key carried-forward risk: business faces significant risks including those not presently known or currently deemed immaterial
+1 more insights

Quarterly Financial Summary
XBRL

Revenue

$1.0B

Net Income

$131M

Gross Margin

67.9%

Operating Margin

20.8%

Net Margin

12.8%

ROE

1.6%

Total Assets

$12.4B

Source: XBRL data from Cooper Companies (The) Q1 2026 10-Q filing on SEC EDGAR. All figures in USD.

Other Cooper Companies (The) Quarterly Reports

Get deeper insights on Cooper Companies (The)

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.